[CAS NO. 500-98-1] Phenylacetylglycine
PRODUCTS SPECIFICATIONS [500-98-1]
DESCRIPTION [500-98-1]
Overview
| MDL | MFCD00021744 |
|---|---|
| Molecular Weight | 193.20 |
| Molecular Formula | C10H11NO3 |
| SMILES | O=C(O)CNC(CC1=CC=CC=C1)=O |
Summary
Phenylacetylglycine is a gut microbial metabolite that can activate β2AR . Phenylacetylglycine protects against cardiac injury caused by ischemia/reperfusion [1] .
IC50 & Target
|
β2 adrenoceptor |
Microbial Metabolite |
Human Endogenous Metabolite |
In Vitro
Phenylacetylglycine (10-100 μM; 30 min before H/R injury) reduces disreoxygenation (H/R) injury-induced apoptosis and activates Gαi and Gαs signaling in neonatal mouse cardiomyocytes (NMCMs) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Apoptosis Analysis [1]
| Cell Line: | Neonatal mouse cardiomyocytes (NMCMs) |
| Concentration: | 10, 33 and 100 μM |
| Incubation Time: | Half an hour before H/R injury |
| Result: | Inhibited disreoxygenation injury induced apoptosis. |
Western Blot Analysis [1]
| Cell Line: | Neonatal mouse cardiomyocytes (NMCMs) |
| Concentration: | 10, 33 and 100 μM |
| Incubation Time: | Half an hour before H/R injury |
| Result: | Significantly decreased the ratio of Bax/Bcl2 and cleaved-caspase 3 expression. Enhanced p-PI3K protein expression. cAMP levels were increased in the early stage and then gradually decreased. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 517.60 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 5.1760 mL | 25.8799 mL | 51.7598 mL |
| 5 mM | 1.0352 mL | 5.1760 mL | 10.3520 mL |
| 10 mM | 0.5176 mL | 2.5880 mL | 5.1760 mL |
Synonyms
